DOI QR코드

DOI QR Code

Evaluation and Optimization of a Serum-based Minimum Inhibitory Concentration Assay to Caspofungin in Candida albicans Clinical Isolates

  • Yoo, Young Bin (Department of Biomedical Laboratory Science, College of Medical Sciences, Konyang University) ;
  • Kim, Sung-Soon (Department of Biomedical Laboratory Science, College of Medical Sciences, Konyang University) ;
  • Kim, Young Kwon (Department of Biomedical Laboratory Science, College of Medical Sciences, Konyang University) ;
  • Kim, Sunghyun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
  • Received : 2016.09.27
  • Accepted : 2017.01.06
  • Published : 2016.12.31

Abstract

In the present study, a serum-based minimum inhibitory concentration (MIC) testing to caspofungin was optimized and evaluated to solve the limitations of the conventional Clinical and Laboratory Standards Institute (CLSI) guideline-based antifungal agent MIC test and the usefulness of this testing for clinical application was determined. A total of 105 Candida albicans clinical isolates were used for measuring MIC to caspofungin. Results showed that growth characteristics were different according to types of serum and the mouse serum was the most suitable for this assay. In order to measure the optimal concentration of mouse serum, 0 to 100% mouse serum were added to the media during fungal culture. The optimal concentration of serum was 50% when consideration of antifungal agent administration and inoculum size, serum components and ease of hyphae separated, and the consideration of the degree of growth. In comparison of the usefulness between the conventional Alamar-modified broth microdilution MIC assay and 50% mouse serum-based MIC testing, the range of $MIC_{80}$ of the Alamar-modified broth microdilution MIC assay was $0.13{\sim}2.0{\mu}g/mL$ (SD ${\pm}0.42{\mu}g/mL$) and that of the 50% mouse serum-based MIC assay was $2.0{\sim}32.0{\mu}g/mL$ (SD ${\pm}9.01{\mu}g/mL$). The range of $MIC_{50}$ of the Alamar-modified broth microdilution MIC assay was $0.13{\sim}2.0{\mu}g/mL$ (SD ${\pm}0.40{\mu}g/mL$) and that of the 50% mouse serum-based MIC assay was $1.0{\sim}16.0{\mu}g/mL$ (SD ${\pm}2.36{\mu}g/mL$). The MICs of 50% mouse serum-based MIC testing was increased by up to 4 to 64 times than Alamar-modified broth microdilution MIC assay. In conclusion, a 50% mouse serum-based MIC assay was more useful for measuring MIC in Candida albicans clinical isolates than conventional colorimetric broth microdilution MIC testing.

Keywords

References

  1. Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller MA, Rinaldi MG, Schell W, Walsh TJ. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J Clin Microbiol. 2007. 45: 2180-2182. https://doi.org/10.1128/JCM.00399-07
  2. Foldi R, Szilagyi J, Kardos G, Berenyi R, Kovacs R, Majoros L. Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology. Diagn Microbiol Infect Dis. 2012. 73: 338-342. https://doi.org/10.1016/j.diagmicrobio.2012.05.011
  3. Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidasis in a neonatal intensive care unit. J Pediatr. 2005. 147: 166-171. https://doi.org/10.1016/j.jpeds.2005.04.016
  4. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008. 46: 120-128. https://doi.org/10.1086/524071
  5. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L. Effects of serum on in vitro susceptibility testing of echomocandins. Antimicrob Agents Chemother. 2007. 51: 4214-4216. https://doi.org/10.1128/AAC.01589-06
  6. Park SD, Uh Y, Jang IH, Yoon KJ, Shin JH. Comparison of ATB FUNGUS 2 and VITEK-2 antifungal susceptibility (ASTYS01) tests for Candida species isolated from blood culture. Korean J Clin Microbiol. 2010. 13: 114-120. https://doi.org/10.5145/KJCM.2010.13.3.114
  7. Pfaller MA, Grant C, Morthland V, Rhine Chalberg J. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J Clin Microbiol. 1994. 32: 506-509.
  8. Pfaller MA, Messer SA, Coffmann S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using microdilution methods to test five antifungal agents, including the new triazole. J Clin Microbial. 1995. 33: 1094-1097.
  9. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs and modes of transmission. Clin Infect Dis. 1996. 22: 89-94. https://doi.org/10.1093/clinids/22.Supplement_2.S89
  10. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis. 1997. 24: 766-784.
  11. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbial Rev. 2001. 14: 643-658. https://doi.org/10.1128/CMR.14.4.643-658.2001
  12. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturvedi V, Ghannoum MA, Espinel-Igroff A, Knapp CC, Ostrosky-Zeichner L, Pfaller MA, Sheehan DJ, Walsh TJ. Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI. 2008.
  13. Shin JH, Lim WH, Shin DH, Suh SP, Ryang DW. Candida species isolated from clinical specimens and medical personnel. Korean J Infect Dis. 1999. 31: 481-486.
  14. Tiballi RN, He X, Zarins LT, Revankar SG, Kauffman CA. Use of a colorimetric system for yeast susceptibility testing. J Clin Microbio. 1995. 33: 915-917.
  15. To WK, Fothergill AW, Rinaldi MG. Comparative evaluation of macrodilution and Alamar colormetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1995. 33: 2660-2664.
  16. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004. 351: 1391-1402. https://doi.org/10.1056/NEJMoa040446
  17. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbial Rev. 1998. 11: 382-402.